GlassScriptPhysician profile
Jogin Jose
NPI 1417489238
$5,676.54
in general payments reported to CMS, 2019-2025
25 companies · $978 in 2025
The $978 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.57 · 2021: $575 · 2022: $675 · 2023: $2,508 · 2024: $889 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857 · Consulting Fee: $1,500 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.75 |
| Consulting Fee | $1,500.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,944.80 | 2022-2025 | |
| Alcon Vision LLC | $825.42 | 2021-2025 | Clareon, Argos, Rocklatan |
| New World Medical,INC. | $489.00 | 2022-2025 | Ahmed Glaucoma Valve, Streamline, Via360 |
| Amgen INC. | $298.17 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $276.37 | 2022-2025 | Vyzulta, Lotemax Sm, Prolensa |
| Allergan, INC. | $188.87 | 2021-2022 | |
| Biotissue Holdings INC. | $186.68 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $182.18 | 2021-2023 | Tecnis Iol, Tecnis Simplicity |
| Sight Sciences, INC. | $155.53 | 2021-2024 | Omni Surgical System |
| Oyster Point Pharma, INC. | $154.02 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $146.76 | 2021 | |
| Sun Pharmaceutical Industries INC. | $144.49 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $128.47 | 2024-2025 | Xdemvy |
| Rxsight INC | $84.04 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Rayner Intraocular Lenses Limited | $79.18 | 2024 | Rayone Aspheric, Omidria, Rayone Emv |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.18 | 2022 | |
| Harrow Eye, LLC | $61.28 | 2024-2025 | Vevye |
| Ivantis, INC | $58.12 | 2021 | |
| Akorn Operating Company LLC | $42.11 | 2021 | |
| Iridex Corporation | $41.06 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.19 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $24.51 | 2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $21.28 | 2024 | Acthar |
| Ocular Therapeutix, INC. | $14.78 | 2025 | Dextenza |
| Apellis Pharmaceuticals, INC. | $14.05 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jogin Jose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.